Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728

HER2‐targeting antibodies (trastuzumab, pertuzumab) and a HER2‐directed antibody‐drug conjugate (trastuzumab emtansine: T‐DM1) are used for the treatment of HER2‐overexpressing breast cancer. However, these treatments eventually become ineffective due to acquired resistance and there is an urgent ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Irie, Hiroki, Kawabata, Rumi, Fujioka, Yayoi, Nakagawa, Fumio, Itadani, Hiraku, Nagase, Hideki, Ito, Kimihiro, Uchida, Junji, Ohkubo, Shuichi, Matsuo, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293079/
https://www.ncbi.nlm.nih.gov/pubmed/32248641
http://dx.doi.org/10.1111/cas.14407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293079/
https://www.ncbi.nlm.nih.gov/pubmed/32248641
http://dx.doi.org/10.1111/cas.14407

Ejemplares similares